Health and Healthcare
Chelsea Therapeutics Rally -- Speculation or Desperation?
Published:
Last Updated:
Chelsea Therapeutics International Ltd. (NASDAQ: CHTP) is rallying on Wednesday after a report in Seeking Alpha called its Northera, a treatment for symptomatic neurogenic hypotension in Parkinson’s patients, a shoe-in for approval, along with the note that shares could rise 100% from here.
Note that the article’s writer does own shares of Chelsea Therapeutics. That always makes for an interesting argument, even when you disclose that you are in fact talking up your book.
Chelsea shares are up almost 9% at $2.01 so far this morning. However, this is a mere $134 million company by market cap. The 52-week trading range is $0.70 to $4.21, and shares have traded all over the place, from $1.50 to about $7 since 2005. Nearly 4 million shares have traded hands today, versus an average daily volume of just under 1.5 million shares, so this is already within striking distance of a 200% alert above normal daily trading volume.
This stock does trade stock options, but the open interest is rather thin for the April, May and June expirations. At $2.00, some traders would argue that the stock is already trading like an option.
Chelsea is one of those companies that should be called unsuitable for widows and orphans.
Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Get started right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.